Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA
Launched by DEPUY ORTHOPAEDICS · Feb 7, 2006
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
This study will evaluate the clinical performance of rotating platform and fixed bearing knee implants. This will be done by obtaining a series of primary total knee replacements. Patients will receive either the P.F.C.® Sigma™ Rotating Platform Cruciate Retaining Knee System or the P.F.C.® Sigma™ Fixed Cruciate Retaining Knee System and assignment is randomized.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Osteoarthritis
- • Rheumatoid Arthritis
- • Other inflammatory arthritis
- • Avascular necrosis of bone
- Exclusion Criteria:
- • Prior ipsilateral TKA
- • Metabolic disorders
- • Joint replacement due to autoimmune disorders
Trial Officials
Tammy L O'Dell, EMT, CCRA, CCRC
Study Director
DePuy Orthopaedics
About Depuy Orthopaedics
DePuy Orthopaedics, a subsidiary of Johnson & Johnson, is a leading global provider of orthopedic medical devices, specializing in the development, manufacturing, and marketing of innovative solutions for joint reconstruction, trauma, and spinal care. With a commitment to advancing patient outcomes through cutting-edge technology and evidence-based practices, DePuy Orthopaedics actively engages in clinical trials to evaluate the safety and efficacy of its products. The company collaborates with healthcare professionals and institutions to ensure that its offerings meet the highest standards of quality and effectiveness, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Billings, Montana, United States
Vancouver, Washington, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
